AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc.

AN2 Therapeutics develops therapies for rare, chronic, and serious infectious diseases using their boron chemistry platform. Self-described as having a pipeline of novel boron-based compounds.

AN2 Therapeutics

AN2 Therapeutics | 1,734 followers on LinkedIn. Developing therapies for rare, chronic, and serious infectious diseases | AN2 Therapeutics, Inc. is a biopharmaceutical company dedicated to developing therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet needs.  Founded by a team of experienced industry leaders in infectious disease drug research and development and boron chemistry, we have a passion for addressing the challenges of infectious disease and improving global human health.   For more information, please visit www.an2therapeutics.com.

Sanjay Chanda

Executive Director, Clinical Operations

Kevin O'Shea

CEO & Co-Founder at AN2 Therapeutics

Eric Easom

Chief Financial Officer | Board Member

Stephanie Wong

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

AN2 Therapeutics supports the companionship that pets provide. Earlier this week we welcomed Taiko, Hiero, Niall, Blue, Piper, Peanut, Lizzie, and Elroy to our offices in Menlo Park.

Back from #ATS2024 ! We’re excited to have connected with healthcare professionals and clinicians supporting patients with rare, chronic and serious pulmonary diseases. #ATS

April 14 is #WorldChagasDay . We take this important opportunity to draw attention to this neglected disease that affects ~6 to 7 million people globally. We are proud to advance our preclinical drug candidate AN2-502998 (formerly AN15368) as a potential new treatment for patients with #ChagasDisease .

Today is #WorldNTDDay , a day where we raise awareness for the neglected tropical diseases that affect the world’s most vulnerable populations. At AN2 we have a passion for addressing the challenges of infectious diseases and improving global human health. #WorldNTDDay #research #Chagas #neglectedtropicaldiseases

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	51 -	132K 258,723.53%	1.06M 705.30%	2.12M 99.62%	2.68M 26.11%
accumulated other comprehensive income loss			-27K -	-374K 1,285.19%	275K 173.53%
cash and cash equivalents	5.60M -	4.07M 27.30%	12.10M 197.22%	27.22M 125.01%	15.65M 42.51%
cash and short term investments	5.60M -	4.07M 27.30%	58.55M 1,338.70%	96.06M 64.05%	107.30M 11.70%
common stock
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	728 -			53K -
long term investments			3.49M -	3.22M 7.66%	27.19M 744.80%
net debt	-5.60M -	-4.07M 27.30%	-12.10M 197.22%	-27.17M 124.57%	-15.65M 42.40%
net receivables					1.40M -
other assets					1 -
other current assets	102K -	164K 60.78%	1.55M 845.73%	2.56M 65.18%	1.81M 29.27%
other current liabilities	158.95K -	1.33M 734.86%	2.33M 75.73%	5.01M 114.88%	11.37M 126.84%
other liabilities
other non current assets			1.72M -	667K 61.31%	1.04M 56.37%
other non current liabilities	727.27K -			-51K -
othertotal stockholders equity				82.91M -	278.88M 236.37%
preferred stock	10.61M -			102.56M -
property plant equipment net				53K -
retained earnings	-5.80M -	-20.32M 250.27%	-47.38M 133.20%	-89.72M 89.35%	-154.46M 72.15%
short term debt				53K -
short term investments			46.46M -	68.84M 48.18%	91.65M 33.13%
tax assets
tax payables
total assets	5.70M -	4.23M 25.72%	65.32M 1,442.65%	102.56M 57.02%	138.74M 35.28%
total current assets	5.70M -	4.23M 25.72%	60.11M 1,319.60%	98.62M 64.08%	110.51M 12.05%
total current liabilities	159K -	1.46M 817.61%	3.40M 132.69%	7.19M 111.66%	14.04M 95.42%
total debt				53K -
total investments			49.94M -	72.06M 44.28%	118.84M 64.92%
total liabilities	887K -	24.55M 2,668.09%	112.73M 359.12%	7.19M 93.62%	14.04M 95.37%
total liabilities and stockholders equity	5.70M -	4.23M 25.72%	65.32M 1,442.65%	102.56M 57.02%	138.74M 35.28%
total non current assets			5.21M -	3.94M 24.40%	28.24M 616.86%
total non current liabilities	728K -	23.09M 3,072.25%	109.33M 373.42%	2K 100.00%
total stockholders equity	4.81M -	-20.32M 522.17%	-47.41M 133.33%	95.37M 301.16%	124.70M 30.75%

COM:AN2THERAPEUTICS

AN2 Therapeutics

Last Close

1.23

22/11 21:00

Market Cap

77.56M

Beta: -

Volume Today

1.25M

Avg: -

Preview